Zymeworks (NYSE, TSX:ZYME) and Daiichi Sankyo entered into a new license agreement, building on their 2016 cross-licensing and collaboration agreement. “With a successful track record and our first bispecific antibody...
3D Signatures (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) recently received a patent from the Canadian Intellectual Property office, which protects the company’s IP in the area of cognitive diseases in general and...
The Chinese Food and Drug Administration (CFDA) has approved Profound Medical’s (TSXV:PRN; OTCQX:PRFMF) Sonalleve for the non-invasive treatment of uterine fibroids. Sonalleve is a therapeutic platform that combines...
NanoSphere Health Sciences (CSE:NSHS; OTC:NSHSF) has joined forces with Vertical Companies, the largest fully integrated company in the legal medical cannabis industry, to launch NanoSphere’s Evolve product line in...
Achaogen (NASDAQ:AKAO) received a mixed review from an FDA advisory committee on its antibiotic, plazomicin, with a vote in favor of approval for complicated urinary tract infections but against its use in bloodstream...
The FDA has released Theratechnologies (TSX:TH) from post-approval commitments related to the approval of EGRIFTA. When the FDA approved EGRIFTA in 2010, the agency requested that the company conduct two large safety...
Closely-held Saniona of Denmark has obtained approval to initiate the second part of its Phase 2a trial for Tesomet in adolescents with Prader-Willi syndrome (PWS), the most common genetic cause of life-threatening...
Adocia (Euronext Paris:FR0011184241 – ADOC) and Tonghua Dongbao Pharmaceuticals (Shanghai Stock Exchange 600867) announced a strategic partnership, giving Tonghua exclusive development and commercialization rights in...
Theratechnologies (TSX:TH) plans to seek regulatory approval from the European Medicines Agency (EMA) for Trogarzo using efficacy and safety data from clinical trials submitted to the FDA. “Based on our discussions, we...
Closely-held CellAegis Devices entered into a definitive agreement with Cardiologic, for the marketing and distribution of its autoRIC device in the UK and Ireland. “This marks the first distribution agreement for the...
Oramed Pharmaceuticals (NASDAQ, TASE:ORMP) has begun screening patients in its 90-day dose-ranging pivotal Phase 2b HbA1c clinical study of its oral insulin capsule, ORMD-0801. A statistically significant improvement in...
Health Canada has approved the sale of Probuphine, a subdermal implant developed by Titan Pharmaceuticals (NASDAQ:TTNP), for the management of opioid dependence in patients clinically stabilized on no more than 8 mg of...
The Peripheral and Central Nervous System Drugs Advisory Committee of the FDA unanimously recommended supporting the approval of the NDA from GW Pharmaceuticals (NASDAQ:GWPH) and its U.S. subsidiary Greenwich...
Closely-held Angel Medical Systems has received FDA premarket approval for the AngelMed Guardian System, an implantable cardiac monitor with patient alerting capability and an additional external alarm device. The...
Novocure (NASDAQ:NVCR) reported positive top-line results from its STELLAR Phase 2 pilot trial in mesothelioma. The data demonstrate clinically meaningful improvements in overall survival and progression free survival...
Eiger BioPharmaceuticals (NASDAQ:EIGR) presented additional positive lonafarnib (LNF) data from the LOWR hepatitis delta virus (HDV) program at the International Liver Congress 2018 in Paris. A sub-analysis of the LOWR...
Paradigm Capital has made Profound Medical (TSXV:PRN; OTCQX:PRFMF) its second quarter Top Pick, saying the next three-to-four months are expected to be an accretive time for Profound. Analyst Rahul Sarugaser writes that...
CymaBay Therapeutics (NASDAQ:CBAY) presented new data from a second interim analysis of its ongoing Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC), a type of liver disease that damages...
Arbutus Biopharma (NASDAQ:ABUS) and closely-held Roivant Sciences of Switzerland agreed to launch Genevant Sciences, a jointly-owned company focused on the discovery, development, and commercialization of a broad range...
BiondVax Pharmaceuticals (NASDAQ:BVXV) enrolled the first participant in a U.S. Phase 2 clinical trial of its universal flu vaccine candidate, M-001. The trial is sponsored by the U.S. National Institute of Allergy and...
Closely-held CellAegis Devices has enrolled the first patients in a U.S. pivotal trial of its autoRIC device, which automatically delivers remote ischemic conditioning (RIC) to provide a non-invasive, cardio-protective...
Ortho Regenerative Technologies (CSE:ORTH) reported positive preliminary MRI outcomes data from a study examining its Ortho-R technology in the biologic repair of rotator cuff injuries. Conducted by researchers from...